The journals of gerontology. Series A, Biological sciences and medical sciences
-
J. Gerontol. A Biol. Sci. Med. Sci. · Oct 2017
Randomized Controlled Trial Multicenter StudyBaseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.
There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. ⋯ Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.